Logo

    Nephrology

    en115 Episodes

    People also ask

    What is the main theme of the podcast?
    Who are some of the popular guests the podcast?
    Were there any controversial topics discussed in the podcast?
    Were any current trending topics addressed in the podcast?
    What popular books were mentioned in the podcast?

    Episodes (115)

    Ultrasound Renal Denervation: Interdisciplinary Approach to Better Patient Outcomes

    Ultrasound Renal Denervation: Interdisciplinary Approach to Better Patient Outcomes
    Host: Naomi Fisher, MD
    Guest: Florian Rader, MD

    Dive into the realm of hypertension management through a chapterized expert interview CME activity on ultrasound renal denervation. In the first chapter, explore the significance of addressing hypertension. Delve into the sympathetic nervous system, ultrasound renal denervation mechanism, and clinical trial data in the second chapter. The third chapter offers dual perspectives on the role of the Hypertension Center, and walks learners through the development process for effective implementation. Gain comprehensive insights from leading experts, Drs. Naomi Fisher and Florian Rader, in this educational series.

    Practical Management of Variceal Bleeding and Hepatorenal Syndrome

    Practical Management of Variceal Bleeding and Hepatorenal Syndrome
    Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
    Guest: Andrew Keaveny, MD
    Guest: Don Rockey, MD

    Extrahepatic manifestations of decompensated cirrhosis confer significant additional risks for mortality, and a multidisciplinary team of healthcare professionals is involved in the care of these patients. This program will discuss two critical aspects of advanced liver disease: variceal bleeding and hepatorenal syndrome (HRS). These complications pose significant challenges in the management of patients with cirrhosis. Clinically-significant portal hypertension, identified by a hepatic venous pressure gradient >10mmHg, predicts the development of variceal hemorrhage, hepatic encephalopathy, ascites, and HRS, all hallmarks of decompensation and multi-organ failure. Faculty will discuss a common patient presentation to highlight best practices in evidence-based care of patients with variceal bleeding and HRS/acute kidney injury.

    Case-Based Management of Hyperkalemia to Optimize RAASi Therapy in Patients with CKD

    Case-Based Management of Hyperkalemia to Optimize RAASi Therapy in Patients with CKD
    Host: Mikhail Kosiborod, MD
    Guest: Biff F. Palmer, MD

    Delve into refining the management of hyperkalemia in CKD patients and their associated comorbidities, striking a delicate balance that preserves guideline-recommended RAASi therapy. Join Dr. Biff Palmer and Dr. Mikhail Kosiborod as they guide the exploration of novel potassium binders for optimal hyperkalemia management, all while upholding the integrity of established treatment guidelines.

    Improving CKD Awareness: Emphasizing the Risk in Patients Who Are Unaware

    Improving CKD Awareness: Emphasizing the Risk in Patients Who Are Unaware
    Host: Ashley Baker, MSN, PMHNP
    Guest: Chi D. Chu, MD, MAS

    The National Health and Nutrition Examination Survey found that kidney disease awareness among patients in the U.S. is very low. And alarmingly, the proportion of awareness has not changed much over the 15-year period of this study. To uncover more of the findings and how to improve CKD awareness, tune into this discussion with Psychiatric Nurse Practitioner Ashley Baker as she takes a deep dive with Dr. Chi D. Chu, Assistant Professor of Medicine in the Division of Nephrology at the University of California San Francisco and coauthor of the article published in the American Journal of Kidney Diseases, titled “CKD Awareness Among US Adults by Future Risk of Kidney Failure.

    ASCO GU 2024: Reviewing Updated Practice Guidelines for Prostate Cancer

    ASCO GU 2024: Reviewing Updated Practice Guidelines for Prostate Cancer
    Guest: Jessica E. Hawley M.D. M.S.

    The National Comprehensive Cancer Network (NCCN) has recommended new guidelines for the treatment of prostate Cancer. In this episode, you’ll learn about the top three biggest changes to the NCCN guidelines. Tune in with Dr. Jessica Hawley, Assistant Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine, who will also present this topic at the ASCO GU Symposium 2024.

    AHA Identifies CKM Syndrome: A First Step in Managing Patients with CVD

    AHA Identifies CKM Syndrome: A First Step in Managing Patients with CVD
    Host: Javed Butler, MD, MBA, MPH
    Guest: Chiadi Ndumele, M.D., Ph.D., M.H.S.

    For the first time, the American Heart Association (AHA) has identified cardiovascular-kidney-metabolic (CKM) syndrome, which reflects a strong overlap between heart disease, kidney disease, and obesity. The major clinical consequence of CKM syndrome is multi-organ dysfunction with a particularly high incidence and burden of cardiovascular disease (CVD), and the result of this is premature morbidity and mortality. So as a result, recognizing CKM syndrome is the first step in earlier diagnosis and treatment. Dive into this episode with Dr. Javed Butler who’s joined by Dr. Chiadi Ndumele, Associate Professor of Medicine and the Director of Obesity and Cardiometabolic Research at Johns Hopkins University.

    A Review of Kidney Biopsy in Complement-Mediated Kidney Diseases

    A Review of Kidney Biopsy in Complement-Mediated Kidney Diseases
    Guest: Mark Haas, MD

    Kidney biopsy is the gold standard for the diagnosis of immunoglobin A (IgA) nephropathy and complement 3 glomerulopathy (C3G),1,2 and the accurate interpretation of kidney biopsy findings is important not only for diagnosis but also guiding clinical management of these conditions. Learn more about what the diagnostic process and findings for IgA nephropathy and C3G look like with Dr Mark Haas, a renal pathologist at Cedars-Sinai Medical Center in Los Angeles.

    References:

    1. Mehdi A, Taliercio JJ. Cleve Clin J Med. 2023;90(6)(suppl 1):e1-e4. doi:10.3949/ccjm.90.e-s1.02
    2. Caravaca-Fontán F, Lucientes L, Cavero T, Praga M. Nephron. 2020;144(6):272-280. doi:10.1159/000507254

    319698 12/23

    The Complement System in the Pathogenesis of IgA Nephropathy

    The Complement System in the Pathogenesis of IgA Nephropathy
    Guest: Richard Lafayette, MD, FACP

    Insights into the complement system are critical to our understanding of the pathogenesis of immunoglobin A (IgA) nephropathy.1 That’s why Dr. Richard Lafayette is here to share what we currently know about the complement system and its role in IgA nephropathy. Dr. Lafayette is a nephrologist at Stanford University Medical Center in California.

    References:

    1. Medjeral-Thomas NR, O'Shaughnessy MM. Adv Chronic Kidney Dis. 2020 Mar;27(2):111-119. doi: 10.1053/j.ackd.2019.12.004

    319698 12/23

    The Four-Hit Model of IgA Nephropathy Pathogenesis

    The Four-Hit Model of IgA Nephropathy Pathogenesis
    Guest: Jai Radhakrishnan, MD

    The most widely accepted mechanism for the pathogenesis of immunoglobin A (IgA) nephropathy is referred to as the “four-hit model,” which is a sequence of four events that can occur.1-3 Here to break down each of those four stages is Dr. Jai Radhakrishnan, a nephrologist at Columbia University Medical Center in New York.

    References:

    1. Knoppova B, Reily C, King RG, et al. J Clin Med. 2021;10(19):4501. doi:10.3390/jcm10194501
    2. Maillard N, Wyatt RJ, Julian BA, et al. J Am Soc Nephrol. 2015;26(7):1503-1512. doi:10.1681/ASN.2014101000
    3. Chang S, Li X-K. Front Med (Lausanne). 2020;7:92. doi:10.3389/fmed.2020.00092

    319698 12/23

    Addressing Issues of CV Mortality in Clinical Trials with IV Iron: Are We Still Getting a Medical Benefit?

    Addressing Issues of CV Mortality in Clinical Trials with IV Iron: Are We Still Getting a Medical Benefit?
    Host: Stefan D. Anker, MD, PhD
    Guest: John Cleland, MD
    Guest: Piotr Ponikowski, MD, PhD, FESC, FHFA

    Iron deficiency is a common heart failure comorbidity with a negative impact on patients’ quality of life and mortality. Recent world events may have influenced clinical trial outcomes with IV iron in heart failure, and secondary analysis has become commonplace. Are the findings still clinically relevant, and are we still getting a clinical benefit? Join Drs. Stefan Anker, Piotr Ponikowski, and John Cleland as they differentiate the design of IV iron trials and break down the relevance of key clinical endpoints. Are we still asking the right questions?

    Hyperkalemia in CKD and HFrEF…What Am I Missing?

    Hyperkalemia in CKD and HFrEF…What Am I Missing?
    Host: George L. Bakris, MD, FAHA, FASN
    Guest: David Bushinsky, MD
    Guest: Lars Lund, MD

    Hyperkalemia is a limiting factor when treating patients with heart failure and CKD on RAASi therapy. It’s especially challenging when these patients are on chronic hemodialysis. Join Drs. George Bakris, David Bushinsky, and Lars Lund as they identify the barriers of optimal treatment in patients on hemodialysis and discuss the real-world evidence using potassium-lowering agents in challenging patient group.

    Clinical Implications of the Evidence from IV Iron Trials in Heart Failure

    Clinical Implications of the Evidence from IV Iron Trials in Heart Failure
    Host: Stefan D. Anker, MD, PhD
    Guest: Robert J. Mentz, MD, FHFSA, FACC, FAHA
    Guest: Piotr Ponikowski, MD, PhD, FESC, FHFA

    Iron deficiency is an independent predictor of decreased functional capacity and reduced survival in our patients with heart failure. Multiple clinical trials have addressed the issue, but we continue to struggle with the clinical implications of the data. Join Drs. Stefan Anker, Robert Mentz, and Piotr Ponikowski as they discuss the evidence from IV iron trials in heart failure, past and present, and what the results mean for your practice and patients.

    Is Managing Gout in the Nephrology Clinic a Challenge?

    Is Managing Gout in the Nephrology Clinic a Challenge?
    Host: Richard Johnson, MD
    Guest: Abdul Abdellatif, MD, FASN

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    Is Gout Hiding in the Nephrology Clinic?

    Is Gout Hiding in the Nephrology Clinic?
    Host: Abdul Abdellatif, MD, FASN
    Guest: Richard Johnson, MD

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    What’s New About Gout? Rheumatology Perspective

    What’s New About Gout? Rheumatology Perspective
    Host: Richard Johnson, MD
    Guest: John K. Botson, MD, RPh

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    What’s New About Gout? Nephrology Perspective

    What’s New About Gout? Nephrology Perspective
    Host: Abdul Abdellatif, MD, FASN
    Guest: Richard Johnson, MD

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    Can You Manage Patients With Uncontrolled Gout More Effectively?

    Can You Manage Patients With Uncontrolled Gout More Effectively?
    Host: Abdul Abdellatif, MD, FASN
    Guest: John K. Botson, MD, RPh

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    Treat or Refer: Who Is Responsible for Managing Gout?

    Treat or Refer: Who Is Responsible for Managing Gout?
    Host: John K. Botson, MD, RPh
    Guest: Abdul Abdellatif, MD, FASN

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    Center of the Target: Which Patients Are Most Likely to Develop Gout?

    Center of the Target: Which Patients Are Most Likely to Develop Gout?
    Host: Richard Johnson, MD
    Guest: Abdul Abdellatif, MD, FASN

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    Gout Beyond the Joints: What’s the Hidden Danger?

    Gout Beyond the Joints: What’s the Hidden Danger?
    Host: Richard Johnson, MD

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    Logo

    © 2024 Podcastworld. All rights reserved

    Stay up to date

    For any inquiries, please email us at hello@podcastworld.io